Jan 30 (Reuters) - Moderna's ( MRNA ) Chief Medical

Officer Jacqueline Miller, who led the development of the

company's mRNA-based COVID-19 vaccine Spikevax, will step down

effective March ‌2, the vaccine maker said on Friday.

Miller ​joined Moderna ( MRNA ) in 2020 as the therapeutic ‍area head

for infectious diseases. ⁠Her departure ⁠comes at a pivotal moment

for the company, which ‌is seeking to plug ​the revenue gap left

by waning demand for COVID products and ⁠turn its mRNA ‍platform

into ​a broader, durable franchise.

Over her career, Miller has supported seven novel vaccine

approvals ‍for patients ranging from infants to older adults,

including Moderna's ( MRNA ) Spikevax and respiratory syncytial virus

vaccine mRESVIA, according to the company's website.

Shares of Moderna ( MRNA ) were ​down ‍over 2% in premarket trading.

The company named David Berman as Chief ​Development Officer

beginning from March 2. Miller will remain as a consultant to

the company to assist with the transition, it added.

Before joining Moderna ( MRNA ), Berman served as head of ​research

and development at Immunocore ( IMCR ) and has previously held

senior roles at AstraZeneca ( AZN ) and Bristol-Myers Squibb ( BMY )

.